Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.
Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer, in particular the first-in-class drug, Enfortumab Vedotin, and the pivotal trial resulting in registration together with promising data in combination with checkpoint inhibitors as well as another ADC, Sacituzumab Govitecan, which targets Trop-2. Prof. Srinivas also discusses the development of ADCs for other GU tumour types.
DOWNLOAD SLIDES - PPTX 
Duration 
Language(s)
Downloadable 
4 MIN
Dec 2024 
